Vertex Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	12,218	12,001	11,020	9,869	8,931	7,574
Revenue Growth (YoY)	10.08%	8.90%	11.66%	10.51%	17.91%	22.06%
Cost of Revenue	1,681	1,651	1,531	1,262	1,080	904.2
Gross Profit	10,537	10,350	9,490	8,607	7,850	6,670
Selling, General & Admin	1,850	1,753	1,464	1,137	944.7	840.1
Research & Development	4,005	4,043	8,259	3,690	2,656	3,051
Other Operating Expenses	0.1	381.1	-0.5	-51.6	-57.5	-3.1
Total Operating Expenses	5,856	6,177	9,723	4,775	3,543	3,888
Operating Income	4,681	4,173	-232.9	3,832	4,307	2,782
Interest Income	370	490.9	598.1	614.7	144.6	4.9
Interest Expense	-10.3	-13.3	-30.6	-44.1	-54.8	-61.5
Other Non-Operating Income (Expense)	124.7	-7.7	-86.1	-22.8	-164.8	4.9
Total Non-Operating Income (Expense)	484.4	469.9	481.4	547.8	-75	-51.7
Pretax Income	5,166	4,643	248.5	4,380	4,232	2,730
Provision for Income Taxes	827.4	690	784.1	760.2	910.4	388.3
Net Income	4,338	3,953	-535.6	3,620	3,322	2,342
Net Income to Common	4,338	3,953	-535.6	3,620	3,322	2,342
Net Income Growth	-	-	-	8.96%	41.84%	-13.63%
Shares Outstanding (Basic)	255	256	258	258	256	258
Shares Outstanding (Diluted)	257	258	258	261	259	260
Shares Change (YoY)	-0.98%	0.04%	-1.00%	0.54%	-0.31%	-1.33%
EPS (Basic)	17.01	15.46	-2.08	14.05	12.97	9.09
EPS (Diluted)	16.86	15.32	-2.08	13.89	12.82	9.01
EPS Growth	-	-	-	8.35%	42.29%	-12.44%
Shares Outstanding	254.16	253.99	256.9	257.7	257.01	254.48
Free Cash Flow	3,710	3,194	-790.3	3,337	3,925	2,409
Free Cash Flow Growth	16.17%	-	-	-14.99%	62.97%	-19.55%
Free Cash Flow Per Share	14.42	12.38	-3.06	12.81	15.15	9.27
Gross Margin	86.24%	86.24%	86.11%	87.21%	87.90%	88.06%
Operating Margin	38.31%	34.77%	-2.11%	38.83%	48.23%	36.73%
Profit Margin	35.51%	32.94%	-4.86%	36.68%	37.20%	30.92%
FCF Margin	30.37%	26.61%	-7.17%	33.81%	43.95%	31.80%
EBITDA	4,899	4,383	-25.7	4,013	4,456	2,908
EBITDA Margin	40.09%	36.52%	-0.23%	40.66%	49.89%	38.39%
EBIT	4,681	4,173	-232.9	3,832	4,307	2,782
EBIT Margin	38.31%	34.77%	-2.11%	38.83%	48.23%	36.73%
Effective Tax Rate	16.02%	14.86%	315.53%	17.36%	21.51%	14.22%

Updated May 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q